Aethlon to introduce new adaptive dialysis-like affinity platform technology at C21 partnering conference

Aethlon Medical, Inc. (OTC Bulletin Board: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announces that Chairman and CEO James A. Joyce will present the Aethlon ADAPT™ system in a presentation at the C21 BioVentures™ Life Sciences Partnering Conference on Wednesday, May 26, 2011, at 3:00 p.m. Pacific time at the Meritage Resort in Napa, Calif.  The newly introduced Aethlon ADAPT™ system is an adaptive dialysis-like affinity platform technology that provides a less burdensome medical device regulatory pathway for therapeutic antibodies and other affinity drugs agents.

"The C21 partnering conference is an ideal venue to introduce our Aethlon ADPAPT™ system to senior drug industry executives that are facing increasingly unpredictable regulatory challenges as well as emerging competition from generics and biosimilars," said Mr. Joyce.  "Our platform technology allows marketed drugs, clinical-stage drugs, and agents that previously failed clinical studies to be repurposed within a therapeutic filtration design that results in an expedited and less costly medical device pathway."  

The Aethlon ADAPT™ system allows for the selective removal of disease-related particles from the entire circulatory system without the loss of essential blood components.  It eliminates the need to infuse drug agents into the body as blood filtration occurs ex vivo.  As a result, new devices evolved from this platform will not add drug toxicity or drug-drug interaction risks if combined with other therapies.  The Aethlon ADAPT™ system also provides the potential to immobilize greater quantities of therapeutic drug agents compared with amounts that can be safely administered systemically.  The platform may also be utilized to immobilize a cocktail of drug agents within a single device to address multiple conditions or multiple factors underlying a single disease condition.  

The genesis of the Aethlon ADAPT™ system is the Aethlon Hemopurifier®, a broad-spectrum antiviral device that immobilizes a single lectin-affinity agent to bind circulating viruses, immunosuppressive proteins and disease-enhancing exosomes associated with both infectious diseases and cancer.  Human studies of the Hemopurifier® have demonstrated average viral-load reductions exceeding 50% during four-hour treatment periods in individuals infected with hepatitis C virus (HCV) and HIV, without the administration of antiviral drugs.  Human studies are now testing the ability of the Aethlon Hemopurifier® to improve clinical outcomes in patients receiving HCV drug therapy.

SOURCE Aethlon Medical, Inc.